


RS•C
ROYAL SOCIETY OF CHEMISTRY



medicinal chemistry

PRINCIPLES AND
PRACTICE
Second Edition

edited by F.D.KING

Contents

Contributors		xxi
Abbreviations		xxiii
General References		xxvii
Chapter 1	Drug–Receptor Interactions	1
	<i>Rob Leurs</i>	
1	Introduction	1
2	Receptor Proteins	2
3	Mechanism of Drug Action: Agonism and Antagonism	5
4	Receptor Subtypes	6
5	Drug Selectivity	9
6	Quantification of Drug–Receptor Interactions	10
	The Receptor Binding of Ligands	11
	From Receptor Binding to Effect	15
	The Occupation Theory of Clark	15
	Partial Agonists and Intrinsic Activity	15
	Partial Agonism and Drug Efficacy	16
	Receptor Antagonism	18
7	From Antagonists to Inverse Agonists	21
8	Final Considerations	23
9	Selected Reading	23
Chapter 2	An Introduction to Ion Channels	25
	<i>Brian Cox</i>	
1	Introduction	25
2	Structure, Function and Classification	26
3	Representative Examples	29
	Ligand-gated Channels	29
	Voltage-gated Channels	34
	Inward Rectifier and Miscellaneous Channels	38
4	Conclusion	40
5	References	40

Chapter 3	Intracellular Targets	42
	<i>Eric Hunt, Neil Pearson, Timothy M. Willson and Andrew Takle</i>	
1	Introduction	42
2	Antibacterial Inhibitors of Protein Synthesis	42
3	Bacterial Topoisomerase Inhibitors:	
	Fluoroquinolones	47
	Mode of Action	47
	Structure–Activity Relationships	47
	Conclusions	52
4	Nuclear Receptors	52
	Nature's Gene Switches	53
	The Orphan Nuclear Receptors	55
	Nuclear Receptors as Targets for Drug Discovery	57
5	Protein Kinases	57
	Inhibition of Protein Kinases	59
	Inhibitors of Epidermal Growth Factor Receptor Kinase (EGFR)	60
	Inhibitors of p38 MAP Kinase	61
	Conclusion	62
6	References	62
Chapter 4	Enzyme Inhibitors	64
	<i>David A. Roberts and Walter H.J. Ward</i>	
1	Introduction	64
2	Enzyme Inhibitor Categories	67
	Kinetics of Substrate Utilisation	67
	IC ₅₀ Values Reflect Affinity and Assay Conditions	70
	Mechanisms of Reversible Inhibition, Affinity and Selectivity	72
	Tight Binding Inhibitors	77
	Slow Binding and Irreversible Inhibitors	77
3	Opportunities in Drug Design	79
	Exploitation of Enzyme Kinetics in Drug Discovery	79
	Isothermal Titration Calorimetry	80
	Structure-based Design	81
4	Classes of Enzymes and Examples of Enzyme Inhibitors	82
	Synthetases: Inhibition of Thymidylate Synthase	82

Reductases: Inhibition of Hydroxymethylglutaryl-CoA Reductase (HMG-CoA Reductase)	83
Kinases: Anilinoquinazolines as Inhibitors of Protein Kinases	84
Proteases: Inhibition of Angiotensin Converting Enzyme and Renin	85
5 Concluding Remarks	89
Acknowledgements	89
6 References	90
Additional Reading	90

Chapter 5 **Biological Evaluation of Novel Compounds** 91

Gary W. Price, Graham J. Riley and Derek N. Middlemiss

1 Introduction	91
2 Primary Screens	93
Broad Spectrum Evaluation of Compounds	99
SB-236057	100
3 Secondary Assays	101
<i>In Vitro</i> Evaluation of Compounds	101
Binding Assays in Native Tissue <i>versus</i> Recombinant Systems	101
Evaluation of Functional Activity of Compounds	102
Agonists/Antagonists/Inverse Agonists	102
Assays for Evaluating Functional Activity	103
GTP γ S Binding	104
Reporter Gene Assays	107
Measuring Function in Native Tissues	108
[³ H]5HT Release from Brain Slices	109
4 Drug Metabolism and Pharmacokinetics (DMPK)	111
5 Pharmacodynamic Assays	111
Requirements of a P.D. assay	111
Examples of P.D. assays	112
SB-236057	112
6 Animal Models – Pre-clinical Proof of Concept	113
Proof of Mechanism Models	114
Disease Models	115
7 Acknowledgements	116
8 References	116

Chapter 6	Pharmacokinetics	118
	<i>Phillip Jeffrey</i>	
1	Introduction	118
2	The Process and Terminology of Drug Delivery	119
3	The Blood (or Plasma) Concentration— Time Curve	120
4	Bioavailability	120
5	Clearance	120
6	Volume of Distribution	120
7	Half-life	120
8	'Advanced' Pharmacokinetic	120
9	Conclusions	137
10	References	137
11	Bibliography	137
Chapter 7	Drug Metabolism	138
	<i>Stephen E. Clarke</i>	
1	Introduction	138
2	Distribution of Drug Metabolism Enzymes	138
3	The Drug Metabolising Enzymes	139
	Phase I Metabolising Enzymes	141
	Cytochrome P450	141
	CYP3A4	142
	CYP2D6	145
	CYP2C9	145
	CYP1A2	147
	CYP2C19	147
	CYP2C8	148
	Other Oxidative Enzymes	148
	Flavin Monooxygenase	148
	Monoamine Oxidase	149
	Aldehyde Oxidase	149
	Xanthine Oxidase	150
	Phase II Conjugation	150
	Glucuronidation	150
	Sulfation	151
	Acetylation	151
	Glutathione	152
4	Conclusions	153
5	References and Bibliography	153

Chapter 8	Toxicology in the Drug Discovery Process	155
	<i>Susan M. Evans, Elisabeth George and C. Westmoreland</i>	
1	Introduction	155
2	Overview of Toxicity Assessment in Drug Discovery	157
	Disease Selection, Target Identification and Lead Series Identification	158
	Lead Compound Optimisation/Candidate Compound Selection	159
	Pre-clinical Safety Assessment and Clinical Development	159
3	<i>In Silico</i> Systems for Assessing Toxicity	159
4	Introduction to <i>In Vitro</i> Systems	161
	High Throughput Toxicity Screening	166
	Cytotoxicity Screens Predictive of <i>In Vivo</i> Toxicity	166
	Cytotoxicity Screens Used to Assess <i>In Vitro</i> Therapeutic Indices	168
	Cytotoxicity Screens Used to Validate Potential Drug Candidates in Cellular Pharmacology Screens	168
	<i>In vitro</i> Screens for Specific Toxicities	169
	Genetic Toxicology	169
	Target Organ Toxicity	170
	Hepatotoxicity	171
	Nephrotoxicity	172
	Haematotoxicity	172
5	<i>In Vivo</i> Toxicology in Candidate Selection	173
6	The Use of New Technologies in Safety Assessment	176
	Toxicogenomics	176
	Proteomics	177
	Nuclear Magnetic Resonance	178
7	Summary	179
8	References	179
Chapter 9	Chemical Development	182
	<i>Paul Smith</i>	
1	Introduction	182
2	Illustrative Examples	190

	The Importance of Quality	190
	3,3-Dimethylindoline. An Example of Route Discovery and Development	190
3	Future Trends	192
4	Acknowledgement	193
5	References	193
	Further General Reading	194

Chapter 10 Physicochemical Properties 195

Han van de Waterbeemd

1	Introduction	195
2	Solubility	196
	Dissolution and Solubility	196
	Measurement of Solubility	198
	Calculation of Solubility	199
3	Lipophilicity	200
	Definitions and Lipophilicity Scales	200
	The Information Content in $\log P$	202
	The Major Contributions	202
	$\text{Diff}(\log P^{N-1})$	202
	$\Delta \log P$	202
	Measurement of $\log D/\log P$	202
	From Shake-flask to High Throughput	202
	Difficulties with Alternative Solvent Systems	202
	Estimation of $\log P$ and $\log D$	203
4	Hydrogen Bonding	203
5	Molecular Size	204
6	Ionisation Constants	205
	Ionisation/Protonation State	205
	Estimation of $\text{p}K_a$	206
7	Electronic Properties	207
8	Estimation of Other Molecular Properties	208
	Computational Properties	208
	Ligand-Receptor Interactions	208
9	Relationships to Drug Disposition	210
	Estimation of Gastrointestinal Absorption	210
	Estimation of Brain Penetration	211
	Estimation of Pharmacokinetic Properties	212
10	References	213

Chapter 11	Quantitative Structure–Activity Relationships	215
	<i>David J. Livingstone</i>	
1	Introduction	215
2	Background to QSAR	217
3	Compound Selection	220
4	Describing Chemical Structure	223
5	Building QSAR Models	225
	Multiple Linear Regression	226
	Principle Component Methods	228
	Data Display	230
	Classified Data	232
	3D QSAR	236
6	Artificial Intelligence	238
7	Summary	240
8	References	241
Chapter 12	Computational Chemistry and Target Structure	243
	<i>Colin Edge</i>	
1	Introduction – The Basic Toolkit	243
	Graphics Programs	243
	Protein Modelling Programs	245
	Programs That Combine Receptor and Ligand	246
	Abstract Site Models	246
2	Structural Information for Computational Chemistry	246
	X-ray Crystallography	246
	Nuclear Magnetic Resonance	247
	Structural Databases	247
3	The Use of Structure in Drug Design	248
	Docking and Virtual Screening	248
	Prediction of Binding Energies	249
	<i>De Novo</i> Design	250
4	Related (Homologous) Structures	250
	Protein Sequence Alignment	251
	Homology Modelling	251
	Membrane Proteins – Difficult Cases	252
5	The Absence of Target Structural Information	253
	Quantitative Structure–Activity Relationships	253
	Molecular Descriptors	254

6	When the Target Structure Is Almost Irrelevant	254
	Drug <i>Versus</i> Leads	254
	Drug-like Qualities	255
	Blood–Brain Barrier	256
7	Conclusion	257
8	References	257
Chapter 13	Patent Medicine	260
	<i>Bill Tyrrell</i>	
1	Introduction	260
2	What Are Patents?	262
3	What Is Patentable?	265
	Novelty	265
	Inventive Step	266
	Sufficiency	267
	Utility or ‘Industrial Application’	268
4	‘Patentese’	269
5	Applying for Patents	271
6	Prosecution and Litigation	276
7	Trips and US Practice	278
8	The Biotech Revolution	280
9	Advance Module	283
10	Sites for Sore Eyes	285
11	Conclusion	286
12	References and Notes	287
Chapter 14	An Introduction to Molecular Biology	291
	<i>Ralph Rapley and Robert J. Slater</i>	
1	Introduction	291
2	Nucleic Acids	291
3	Proteins	293
4	The Flow of Genetic Information	294
5	DNA Replication	294
6	Transcription	296
7	RNA Processing	297
8	Protein Synthesis	297
	Activation of Amino Acids	298
	Translation	299
9	The Genetic Code	300
10	Post Translational Modification	302

11	The Control of Transcription and Translation	302
12	Genomics	302
13	Nucleic Acid Analysis and Recombinant DNA Technology	304
	Nucleic Acid Extraction Techniques	304
	Electrophoresis of Nucleic Acids	305
	Restriction Mapping of DNA Fragments	306
	Nucleic Acid Blotting and Hybridisation	307
	Production of Gene Probes	308
	DNA Gene Probe Labelling	309
	The Polymerase Chain Reaction	309
	Elements Involved in the PCR	310
	Primer Design in the PCR	311
	PCR Amplification Templates	312
	Applications of the PCR	313
	Recombinant DNA Technology and Gene Libraries	315
	Digesting Genomic DNA Molecules	315
	Ligating DNA Molecules	315
	Considerations in Gene Library Preparations	316
	Screening Gene Libraries	317
	Screening Expression cDNA Libraries	317
	Nucleotide Sequencing of DNA	319
	PCR Cycle Sequencing	321
	Automated Fluorescent DNA Sequencing	321
	Maxam and Gilbert Sequencing	322
14	Bioinformatics and the Internet	322
15	Human Genome Mapping Project	324
16	References	325

Chapter 15 Strategy and Tactics in Drug Discovery **327**

Frank D. King

1	Introduction	327
2	Target Identification and Validation	328
3	Lead Identification	330
4	Lead Optimisation	332
5	Development Candidate	334
6	Back-up/Follow-up	335
7	Optimising the Chances for Success	335

8	Decision Making in Medicinal Chemistry	338
	Pharmacophore	338
	Bioisosteres	341
	Pharmacophoric Bioisosterism	341
	Template Bioisosterism	341
	Conformational Restriction	342
	Improved Affinity	344
	Improved Selectivity	345
	Improved Chemical/Metabolic Stability	346
	Pro-drugs	347
	Soft Drugs	350
	Data Interpretation	351
	Chemistry	355
9	Patents	357
10	Conclusion	358
11	References	358

Chapter 16 Combinatorial Chemistry: Tools for the Medicinal Chemist 359

Morag A.M. Easson and David C. Rees

1	Introduction	359
2	Concepts in Combinatorial Chemistry	360
	Compound Libraries and Arrays	360
	Mix and Split Synthesis	361
3	Impact of CC on the Drug Discovery Process	363
4	Solid-phase Synthesis of 'Drug-like' Molecules	364
	Linkers and the Solid Support	364
	On-bead Monitoring	366
	Encoded Libraries	366
	Scope of Reactions and Structures on Solid Phase	367
	Singles <i>Versus</i> Mixtures	368
5	Solution-phase Library Synthesis	368
	Strategies for Solution-phase Synthesis	368
	Parallel Solution-phase Libraries	369
	Support-bound Reagents and Scavengers	370
	Multi-component Condensations	371
6	Solid Phase <i>Versus</i> Solution Phase	372
7	Laboratory Automation and Equipment	373
	Revolution at the Bench	373
	Synthesis	374
	Purification	376

	Analysis	376
8	Biological Activity from Compound Libraries	377
	Lead Generation Compound Libraries	377
	Lead Optimisation Compound Libraries	378
	Examples of Library Structures Demonstrating Biological Activity	379
9	Conclusions	379
10	References	381
Chapter 17	The Identification of Selective 5-HT_{2C} Receptor Antagonists: A New Approach to the Treatment of Depression and Anxiety	382
	<i>Steven M. Bromidge</i>	
	1 Introduction to Depression	382
	2 Rationale for 5-HT _{2C} Antagonists in Depression	383
	3 Initial Lead: Identification of SB-200646	383
	4 Conformational Restriction: Identification of SB-206553	384
	5 Molecular and Receptor Modelling Studies	385
	6 Bioisosteric Replacement of the <i>N</i> -Methylindole	387
	7 Identification of Biarylcarbamoylindolines	391
	8 Bispyridyl Ethers: Identification of SB-243213	393
	9 Synthesis of SB-243213	394
	10 Summary	395
	11 References	395
Chapter 18	The Identification of the HIV Protease Inhibitor Saquinavir	397
	<i>Frank D. King</i>	
	1 Introduction	397
	2 Primary Assay	399
	3 Inhibitor Design	399
	Identification of the Minimum Inhibitor Sequence	399
	Optimisation of the N-terminus	400
	Optimisation of the Proline	401
	X-ray Structures	404
	4 Synthesis of Saquinavir	405
	5 Clinical Data	405
	6 Conclusion	406
	7 References	406

Chapter 19	Discovery of Vioxx (Rofecoxib)	407
	<i>Frank D. King</i>	
	1 Introduction	407
	2 Lead Molecules	409
	3 Identification of Rofecoxib (MK-966)	410
	Assays	410
	Medicinal Chemistry	411
	4 <i>In Vivo</i> Activity of Rofecoxib	412
	5 Clinical Results	413
	6 Conclusion	414
	7 References	414
Chapter 20	NK1 Receptor Antagonists	415
	<i>Chris Swain</i>	
	1 Introduction	415
	2 Medicinal Chemistry Programme	416
	Reducing Calcium Channel Activity	417
	Improving the Duration of Action	419
	Non-CNS Penetrant Compounds	421
	3 Profile of MK-869 Clinical Candidate	423
	4 Clinical Results	424
	Emesis	424
	Pain	425
	Psychiatric Indications	426
	Acknowledgements	427
	5 References	427
Appendices		
	1 Ranking of Key Ethical Drug Products in 2000 (US\$ Sales Value)	428
	2 Summary of Receptor Properties	430
	3 Plot of Molar Concentration vs. g ml^{-1} for Different Molecular Weights	440
	4 Table of Molar Concentration vs. g ml^{-1} for Different Molecular Weights	441
	5 Conversion Table for IC_{50} (K_i) to pIC_{50} ($\text{p}K_i$)	441
Subject Index		442